ChAdOx1 MERS候选疫苗的安全性及免疫原性:剂量递增、开放标签、非随机、非对照1期试验
该1期试验在24名健康成人中评估了表达MERS-CoV全长刺突蛋白的黑猩猩腺病毒载体疫苗ChAdOx1 MERS的安全性及免疫原性。单剂肌注5×10^9至5×10^10病毒颗粒安全耐受,无疫苗相关严重不良事件;所有剂量均诱导T细胞和IgG应答,高剂量组44%出现针对活病毒的中和抗体。
要点
- ChAdOx1 MERS单剂接种在最高5×10^10病毒颗粒剂量下安全耐受。
- 所有剂量均显著诱导针对MERS-CoV刺突抗原的T细胞和IgG应答。
- 高剂量组44%受试者产生针对活MERS-CoV的中和抗体。
核心结论
- ChAdOx1 MERS在所有测试剂量下安全且耐受良好,单剂可诱导体液和细胞免疫应答。
研究设计与样本
- 剂量递增、开放标签、非随机、非对照1期试验,在牛津招募24名18-50岁健康成人,随访至12个月。
主要发现
- 24名参与者中低剂量组6人、中剂量组9人、高剂量组9人;12个月时5人失访。
- 124例征集性不良事件中92例(74% [95% CI 66-81])为轻度,31例(25% [18-33])为中度,均为自限性。
- 高剂量组9人中4人(44% [95% CI 19-73])在接种28天后出现针对活MERS-CoV的中和抗体;24人中19人(79% [58-93])在假病毒中和试验中具有中和能力。
临床怎么用
- 支持将ChAdOx1 MERS推进至现场1b期和2期临床试验。
局限性
- 非随机、非对照、开放标签设计,样本量小(24人),12个月时5人失访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection continue to rise in the Arabian Peninsula 7 years after it was first described in Saudi Arabia. MERS-CoV poses a significant risk to public health security because of an absence of currently available effective countermeasures. We aimed to assess the safety and immunogenicity of the candidate simian adenovirus-vectored vaccine expressing the full-length spike surface glycoprotein, ChAdOx1 MERS, in humans. METHODS: This dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial was done at the Centre for Clinical Vaccinology and Tropical Medicine (Oxford, UK) and included healthy people aged 18-50 years with negative pre-vaccination tests for HIV antibodies, hepatitis B surface antigen, and hepatitis C antibodies (and a negative urinary pregnancy test for women). Participants received a single intramuscular injection of ChAdOx1 MERS at three different doses: the low-dose group received 5 × 109 viral particles, the intermediate-dose group received 2·5 × 1010 viral particles, and the high-dose group received 5 × 1010 viral particles. The primary objective was to assess safety and tolerability of ChAdOx1 MERS, measured by the occurrence of solicited, unsolicited, and serious adverse events after vaccination. The secondary objective was to assess the cellular and humoral immunogenicity of ChAdOx1 MERS, measured by interferon-γ-linked enzyme-linked immunospot, ELISA, and virus neutralising assays after vaccination. Participants were followed up for up to 12 months. This study is registered with ClinicalTrials.gov, NCT03399578. FINDINGS: Between March 14 and Aug 15, 2018, 24 participants were enrolled: six were assigned to the low-dose group, nine to the intermediate-dose group, and nine to the high-dose group. All participants were available for follow-up at 6 months, but five (one in the low-dose group, one in the intermediate-dose group, and three in the high-dose group) were lost to follow-up at 12 months. A single dose of ChAdOx1 MERS was safe at doses up to 5 × 1010 viral particles with no vaccine-related serious adverse events reported by 12 months. One serious adverse event reported was deemed to be not related to ChAdOx1 MERS. 92 (74% [95% CI 66-81]) of 124 solicited adverse events were mild, 31 (25% [18-33]) were moderate, and all were self-limiting. Unsolicited adverse events in the 28 days following vaccination considered to be possibly, probably, or definitely related to ChAdOx1 MERS were predominantly mild in nature and resolved within the follow-up period of 12 months. The proportion of moderate and severe adverse events was significantly higher in the high-dose group than in the intermediate-dose group (relative risk 5·83 [95% CI 2·11-17·42], p<0·0001) Laboratory adverse events considered to be at least possibly related to the study intervention were self-limiting and predominantly mild in severity. A significant increase from baseline in T-cell (p<0·003) and IgG (p<0·0001) responses to the MERS-CoV spike antigen was observed at all doses. Neutralising antibodies against live MERS-CoV were observed in four (44% [95% CI 19-73]) of nine participants in the high-dose group 28 days after vaccination, and 19 (79% [58-93]) of 24 participants had antibodies capable of neutralisation in a pseudotyped virus neutralisation assay. INTERPRETATION: ChAdOx1 MERS was safe and well tolerated at all tested doses. A single dose was able to elicit both humoral and cellular responses against MERS-CoV. The results of this first-in-human clinical trial support clinical development progression into field phase 1b and 2 trials. FUNDING: UK Department of Health and Social Care, using UK Aid funding, managed by the UK National Institute for Health Research.
引用
- Folegatti PM, Bittaye M, Flaxman A, et al. Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. Lancet Infect Dis. 2020. PMID: 32325038. doi:10.1016/S1473-3099(20)30160-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。